Moreover, pharmacological inhibition of DCLK1 prevented the development of DCLK1+ pancreatic ductal adenocarcinoma (PDAC) in clinically relevant patient-derived PDAC organoid models.5 Here, DCLK1 is linked to pancreatic ductal adenocarcinoma.